Filtered By:
Drug: Temodar
Countries: UK Health
This page shows you your search results in order of date.
Order by Relevance | Date
Total 16 results found since Jan 2013.
Advanced small-bowel well-differentiated neuroendocrine tumours: An international survey of practice on 3 < sup > rd < /sup > -line treatment
CONCLUSION: Everolimus was the most frequently used therapeutic option in the third-line setting. The most important factors for decision-making included Ki-67, rate of progression, functionality and tumour burden; since this decision is based on multiple factors, it highlights the need for a multidisciplinary assessment.PMID:33776367 | PMC:PMC7968134 | DOI:10.3748/wjg.v27.i10.976
Source: World Journal of Gastroenterology - March 29, 2021 Category: Gastroenterology Authors: Angela Lamarca Mauro Cives Louis de Mestier Joakim Crona Francesca Spada Kjell Öberg Marianne Pavel Teresa Alonso-Gordoa Source Type: research
